Geographic Variations in the Quality of Oral Anticoagulation With Vitamin K Antagonists in the Era of New Anticoagulants
Open Access
- 23 January 2013
- journal article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 2 (1) , e000088
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical TrialJournal of the American Heart Association, 2013
- 2012 focused update of the ESC Guidelines for the management of atrial fibrillationEuropean Heart Journal, 2012
- Stroke prevention in atrial fibrillationCurrent Opinion in Neurology, 2012
- Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillationThrombosis Research, 2012
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculAEuropean Heart Journal, 2011
- Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patientsThrombosis and Haemostasis, 2011
- Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trialThe Lancet, 2010
- Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic RangeCirculation, 2008
- Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial FibrillationCirculation: Cardiovascular Quality and Outcomes, 2008